Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。